___

• 1. Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children previously untreated chronic myelogenous leukemia in early chronic phase. Results of the French national Phase IV trial. J Clin Oncol.2011; 29: 2827-32.
• 2. Krumbholz M, KarlvM, Tauer JT, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia genes chromosomes. Cancer 2012; 51(11): 1045-53.
• 3. Hijiya N, Schultz KR, Metzler M, Millot F, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016; 127(4): 392-9.
• 4. Fall S, Ndiaye FSD, Dior OD, Sall AF, et al. Leucémie myeloide chronique des sujets jeunes: expérience dans une unité d’hématologie Clinique au Sénégal. Revue d’oncologie hématologie pédiatrique. 2015; 3 : 170-4.
• 5.S. O’ Brien, E Berman, H Borghuei, et al. NCCN clinical practice guidelines in oncology. I Natl Compr Cancer Netw. 2009; 7: 987-1020
• 6. El-Affy M, Alaa M, Haddad AL and Ahmed DH. Managelent of chronic myelogenous leukemia in the pediatric age group: imatinib mesylate or SCT. Journal of the Egyptian Nat. Cancer Inst. 2010; 22(4): 227-32.
• 7. Raut L, Bohara VV, Ray SS, Charkrabati P and Chaudhuri V. Chronic myeloid leukemia in children and adolescent: A single center experience from Eastern India. South Asian J. Cancer. 2013; 2(4): 260-4.
• 8. Ngolet LO, Kocko I, Galiba Atipo Tsiba O, et al. Imatinib mesylate in chronic myelogenous leukemia : a Congolese experience. EAMJ. 2016; 93(9): 118- 122.
• 9. Diallo DA,Cissoko LS,Cissoko Y, Diallo Y, Baby M et al. Epidémiologie actuelle des hémopathies malignes dans les services d’hématologie oncologie médicale et de médecine interne de l’hôpital du Point G, Bamako, Mali. Mali Médical. 2005; 20 (4):1-8.
• 10. S. Noens, M.R Van Liende, R De Bock et al. Prevalence, determinants, and outcomes of non adherence to imatinib therapy in patient with chronic myeloid leukemia: the ADAGIO study. Blood. 2009; 22 (113): 5401-11.